Medicure Inc. · TSXV:MPH
Medicure — Investor Presentation (March 2016)
18 slides from Medicure's investor presentation, Mar 31, 2016
Slide 1: Investor Presentation
Investor Presenta,on March 31, 2016 Albert Friesen Chair & CEO Dawson Reimer President & COO James Kinley CFO
Slide 2: Disclaimer
Disclaimer This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: Aggrastat Prescribing Information
Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombo,c cardiovascular events (combined endpoint of death, myocardial infarc,on, or refractory ischemia/repeat cardiac procedure) in pa,ents with non-ST eleva,on acute coronary syndrome (NSTE-ACS). Dosage an
Slide 4: !! \"1]J$;)3$+CP'^8$)/+%$C)%+.$%)&$+B) !! 6"$)'K)&3$)'".F)3'%M1&+.)8+(C1'.'XF) M3+(B+)%+.$%)&$+B%)1")&3$)\RHR)
=&),95.&'>(9?) !"#$%&'()*+"$,(-.(&%/0&()"&1.$(2+"31&/#%4" 12"*,%"4%5%)1$.%2*"(24"&1..%-&'()'6(012"13" *,%-($%/0&#"31-"*,%"7898",1#$'*()".(-:%*8" 8".&'8"+@&-&(9,' ) !! \"1]J$;)3$+CP'^8$)/+%$C)%+.$%)&$+B) !! 6"$)'K)&3$)'".F)3'%M1&+.)8+(C1'.'XF) M3+(B+)%+.$%)&$+B%)1")&3$)\RHR) 4
Slide 5: Net Revenue Growth: 2012 - 2015
Net Revenue Growth: 2012 - 2015 a)2+"+C1+") 'EABCCCBCCC'' 'ECBCCCBCCC'' 'DABCCCBCCC'' ) -8&J+.) 'DCBCCCBCCC'' :%&)3+.K)) <=:_) ) 'ABCCCBCCC'' '2'''' ECDE' ECDF' ECDG' ECDA' Q$&)($#$"J$)K'()&3$)&3($$)+"C)&@$.#$)B'"&3)M$(1'C)$"C$C)?$8$B/$()9:;)<=:_)+($)M($.1B1"+(F)+"C)+($)/+%$C)'")&3$)/$%&)1"K'(B+,'")
Slide 6: EBITDA Growth: 2012 - 2015
EBITDA Growth: 2012 - 2015 *)L5#-&)'M3>N!*O' a)2+"+C1+") 'DCBCCCBCCC'' 'KBCCCBCCC'' 'JBCCCBCCC'' 'GBCCCBCCC'' 'EBCCCBCCC'' '2'''' ECDE' ECDF' ECDG' ECDA' 'HEBCCCBCCCI' I3$)2'BM+"F)C$`"$%)5[!I?-)+%)b$+("1"X%)/$K'($)1"&$($%&;)&+W$%;)C$M($81+,'";)+B'(,c+,'")+"C)'&3$()1"8'B$)'()$WM$"%$b)+"C)-CYJ%&$C)5[!
Slide 7: Acute cardiovascular hospital product
!! Acute cardiovascular hospital product !! I.V. platelet inhibitor; binds the GP IIb/IIIa receptor !! Indicated for Acute Coronary Syndrome (ACS) !! 41% reduction in death and MI in high-risk patients* !! Oct 2013: FDA Approved High Dose Bolus !! Patented until June 2023 !! Sept 2015: sNDA filed fo
Slide 8: Commercial Product: Aggrastat
Commercial Product: Aggrastat® P(,-&)'Q-$-&#'R;'>>ST>>>$'=$.U&-' R."##'PQ!'VEWJ?E'+,44,"(B'X$('Y'!&9'ECDA'' Aggrastat $24.1 million !! Launched by Merck in 1998 !! Is the #1 in class ex-USA !! U.S. rights acquired by Medicure in 2006 Integrilin !! Medicure obtained broader FDA approval in ReoPro $19
Slide 9: Competitive Positioning of Aggrastat
Competitive Positioning of Aggrastat 9
Slide 10: Weekly Bag Demand (Weekly Scripts)
Weekly Bag Demand (“Weekly Scripts”) A'..1"X)9)7'"&3)-#$(+X$)[+X)?$B+"C) 1600 1400 Label 1200 Change Oct 2013 Bags / Week 1000 800 600 400 200 0 10
Slide 11: GPI Treatment Costs in the US
$3,500 GPI Treatment Costs in the US $3,000 Aggrastat: 25 µg/kg § US healthcare system is bolus + 0.15 µg/kg/min financially stressed $2,500 Integrilin: 2x180 µg/kg bolus + 2.0 µg/kg/min § Integrilin often one of the largest $2,000 Reopro: 0.25 mg/kg pharmacy line items $3,126.12 bolus + 0.125 µg/kg
Slide 12: Growth & Business Development
Growth & Business Development !! Building a specialty pharmaceutical portfolio focused on the U.S. hospital market !! Leveraging our sales infrastructure !! Invest in reduced risk - high reward development projects !! Maintain focus on profitability 12
Slide 13: Apicore Transaction: July 2014
Apicore Transaction: July 2014 Z,[&)';.,9&'\@/"(' Z,[&)';.,9&'\@/"(' Z"5()&.#' _R9l) 71"'(1&F) 5]J1&F) H3+($3'.C$() 5]J1&F)1"#$%&'() T'+")k)j+((+"&%) +)M(1#+&$)B+"JK+8&J($()'K)8'BM.$W)+8,#$)M3+(B+8$J,8+.) 1"X($C1$"&%)L-*!%O)+"C)C$#$.'M$()'K)X$"$(18)M('CJ8&%)L-Q?-%O)) 13
Slide 14: Apicore Background
Apicore Background Year Revenue (USD)* 2012 $5 Million 2013 $10.3 Million 2014 $14.3 Million 2015 $23 Million !! API Manufacturer & ANDA Developer Somerset, New Jersey •! Complex synthetic chemistry •! Early & “first to file” generics •! Secure, high quality production !! History: •! Founded in 2004
Slide 15: Key Financial Info – MPH: TSXV
Key Financial Info – MPH: TSXV Cap Structure As of March 31, 2016 Basic Total 14,672,018 Fully Diluted Total 16,848,736 Share Price C$7.09 (as of March 30,2016) Market Cap C$91.0M § Recent Financial Highlights • Q4 Net Revenue Est. $9.5 M • 2015 Net Revenue $22.1 M • 2015 *Adj.EBITDA $9.0 M § 2016 F
Slide 16: Business Vision
Business Vision Aggrastat Quarterly Net Product Sales (CDN Millions) !! To build a large, stable, 'DEBCCCBCCC'' specialty pharmaceutical 'DCBCCCBCCC'' company !! To further expand Aggrastat 'KBCCCBCCC'' revenue 'JBCCCBCCC'' !! To expand revenue with new commercial products 'GBCCCBCCC'' !! To diversi
Slide 17: Aggrastat Prescribing Information
Aggrastat Prescribing Information Indication: AGGRASTAT is indicated to reduce the rate of thrombo,c cardiovascular events (combined endpoint of death, myocardial infarc,on, or refractory ischemia/repeat cardiac procedure) in pa,ents with non-ST eleva,on acute coronary syndrome (NSTE-ACS). Dosage an
Slide 18: Thank you.
Thank you. Contact a Product Specialist Investor Rela/ons 1.800.509.0544 [email protected] 1.888.435.2220 (Ext. 231) For More Informa/on www.medicure.com www.aggrastat.com